In 2011, Yagi and colleagues first described the generation of induced pluripotent stem cells (iPSC)-derived neurons from familial AD (fAD) cases with mutations in PSEN1 and PSEN2 genes, finding that these cells presented higher Aβ1–42 production, which was reduced when cells were treated with specific gamma-secretase inhibitors, suggesting the potential of these cells to serve for identification and validation of candidate drugs [33]. Here, PSEN1 is linked to familial Alzheimer disease.